Trial Profile
A Pilot Study of the Safety and Efficacy of Imatinib in Reducing Monocytosis or Leukocytosis in Patients With Chronic Myelomonocytic Leukemia or Atypical Chronic Myelogenous Leukemia, Respectively.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.